Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on April 11, 2025. The report details a capital raising event involving the Company's subsidiary, Lucid Diagnostics Inc.
Key Financial Metrics
The filing reports the following transaction metrics regarding the subsidiary's offering:
- Shares Sold: 14,375,000 shares of Lucid Diagnostics common stock.
- Offering Price: $1.20 per share.
- Underwriters' Option: 1,875,000 shares included and exercised in full.
- Net Proceeds: Approximately $16.1 million (after underwriting discounts and estimated expenses).
- Use of Proceeds: Working capital and general corporate purposes.
Note: This filing does not provide consolidated revenue, profit, cash flow, margin, debt, or liquidity metrics for Pavmed Inc. or Lucid Diagnostics.
Material Changes
The primary material change is the successful closing of the underwritten public offering by Lucid Diagnostics. The transaction was executed pursuant to an existing shelf registration statement (Form S-3, No. 333-268560) and a prospectus supplement dated April 9, 2025.
Outlook, Risks, and Management Commentary
Management indicates the net proceeds will be utilized for working capital and general corporate purposes. The filing incorporates by reference more detailed descriptions of the offering and related agreements found in Lucid Diagnostics' own Form 8-K filings dated April 10, 2025, and April 11, 2025. No specific risks, contingencies, or forward-looking guidance beyond the use of proceeds are detailed in this specific document.
Investor Verification Checklist
- Verify the final net proceeds received by Lucid Diagnostics against the estimated $16.1 million.
- Review the detailed offering agreements referenced in Lucid Diagnostics' separate 8-K filings (April 10 and 11, 2025).
- Confirm the impact of the subsidiary's equity issuance on Pavmed Inc.'s consolidated balance sheet and ownership structure.
- Monitor subsequent filings for the actual deployment of the raised capital.